Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis
Background: Anti-tumor necrosis factor-α (TNF-α) agents are effective for moderately to severely active ulcerative colitis (UC). Nonetheless, a proportion of patients fail to respond to these agents as therapy for induction of remission. Recent studies indicated that perinuclear anti-neutrophil cyto...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-04-01
|
| Series: | Inflammatory Intestinal Diseases |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/515361 |
| _version_ | 1818609636991827968 |
|---|---|
| author | Atsushi Yoshida Katsuyoshi Matsuoka Fumiaki Ueno Toshio Morizane Yutaka Endo Toshifumi Hibi |
| author_facet | Atsushi Yoshida Katsuyoshi Matsuoka Fumiaki Ueno Toshio Morizane Yutaka Endo Toshifumi Hibi |
| author_sort | Atsushi Yoshida |
| collection | DOAJ |
| description | Background: Anti-tumor necrosis factor-α (TNF-α) agents are effective for moderately to severely active ulcerative colitis (UC). Nonetheless, a proportion of patients fail to respond to these agents as therapy for induction of remission. Recent studies indicated that perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) may predict response to anti-TNF-α agents in UC patients. However, whether PR3-ANCA can predict primary nonresponse (PNR) to anti-TNF-α agents has not yet been evaluated. The aim of this study was to examine whether PR3-ANCA can predict PNR to anti-TNF-α in UC patients. Methods: This was a single-center retrospective study. Data were extracted from 50 patients with UC who had measurements of PR3-ANCA and received anti-TNF-α agents for the first time as induction therapy. The primary endpoint of this study was a proportion of patients with PNR stratified by PR3-ANCA positivity. PNR to anti-TNF-α agents was defined as failure to achieve reduction in partial Mayo score by 2 or more points and change to other therapeutics within 6 weeks. Results: Fourteen (28%) of the 50 patients were PR3-ANCA positive. Seventeen (34%) of the 50 patients demonstrated PNR. Eleven (78.6%) of the 14 PR3-ANCA-positive patients demonstrated PNR, while 6 (16.7%) of the 36 PR3-ANCA-negative patients demonstrated PNR. Multivariate analysis demonstrated that PR3-ANCA positivity was associated with PNR to anti-TNF-α agents (odds ratio 19.29, 95% CI: 3.30–172.67; p = 0.002). Conclusion: PR3-ANCA positivity can predict PNR to anti-TNF-α agents in UC patients. |
| first_indexed | 2024-12-16T15:01:42Z |
| format | Article |
| id | doaj.art-e637bfba8787417b88d0cd3eea53e80b |
| institution | Directory Open Access Journal |
| issn | 2296-9403 2296-9365 |
| language | English |
| last_indexed | 2024-12-16T15:01:42Z |
| publishDate | 2021-04-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Inflammatory Intestinal Diseases |
| spelling | doaj.art-e637bfba8787417b88d0cd3eea53e80b2022-12-21T22:27:16ZengKarger PublishersInflammatory Intestinal Diseases2296-94032296-93652021-04-016211712210.1159/000515361515361Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative ColitisAtsushi Yoshida0Katsuyoshi Matsuoka1Fumiaki Ueno2Toshio Morizane3Yutaka Endo4Toshifumi Hibi5Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, JapanDepartment of Gastroenterology and Hepatology, Toho University Sakura Medical Center, Chiba, JapanCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, JapanCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, JapanCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, JapanCenter for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, JapanBackground: Anti-tumor necrosis factor-α (TNF-α) agents are effective for moderately to severely active ulcerative colitis (UC). Nonetheless, a proportion of patients fail to respond to these agents as therapy for induction of remission. Recent studies indicated that perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) may predict response to anti-TNF-α agents in UC patients. However, whether PR3-ANCA can predict primary nonresponse (PNR) to anti-TNF-α agents has not yet been evaluated. The aim of this study was to examine whether PR3-ANCA can predict PNR to anti-TNF-α in UC patients. Methods: This was a single-center retrospective study. Data were extracted from 50 patients with UC who had measurements of PR3-ANCA and received anti-TNF-α agents for the first time as induction therapy. The primary endpoint of this study was a proportion of patients with PNR stratified by PR3-ANCA positivity. PNR to anti-TNF-α agents was defined as failure to achieve reduction in partial Mayo score by 2 or more points and change to other therapeutics within 6 weeks. Results: Fourteen (28%) of the 50 patients were PR3-ANCA positive. Seventeen (34%) of the 50 patients demonstrated PNR. Eleven (78.6%) of the 14 PR3-ANCA-positive patients demonstrated PNR, while 6 (16.7%) of the 36 PR3-ANCA-negative patients demonstrated PNR. Multivariate analysis demonstrated that PR3-ANCA positivity was associated with PNR to anti-TNF-α agents (odds ratio 19.29, 95% CI: 3.30–172.67; p = 0.002). Conclusion: PR3-ANCA positivity can predict PNR to anti-TNF-α agents in UC patients.https://www.karger.com/Article/FullText/515361inflammatory bowel diseaseprimary failureinfliximabadalimumabgolimumab |
| spellingShingle | Atsushi Yoshida Katsuyoshi Matsuoka Fumiaki Ueno Toshio Morizane Yutaka Endo Toshifumi Hibi Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis Inflammatory Intestinal Diseases inflammatory bowel disease primary failure infliximab adalimumab golimumab |
| title | Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis |
| title_full | Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis |
| title_fullStr | Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis |
| title_full_unstemmed | Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis |
| title_short | Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis |
| title_sort | serum pr3 anca is a predictor of primary nonresponse to anti tnf α agents in patients with ulcerative colitis |
| topic | inflammatory bowel disease primary failure infliximab adalimumab golimumab |
| url | https://www.karger.com/Article/FullText/515361 |
| work_keys_str_mv | AT atsushiyoshida serumpr3ancaisapredictorofprimarynonresponsetoantitnfaagentsinpatientswithulcerativecolitis AT katsuyoshimatsuoka serumpr3ancaisapredictorofprimarynonresponsetoantitnfaagentsinpatientswithulcerativecolitis AT fumiakiueno serumpr3ancaisapredictorofprimarynonresponsetoantitnfaagentsinpatientswithulcerativecolitis AT toshiomorizane serumpr3ancaisapredictorofprimarynonresponsetoantitnfaagentsinpatientswithulcerativecolitis AT yutakaendo serumpr3ancaisapredictorofprimarynonresponsetoantitnfaagentsinpatientswithulcerativecolitis AT toshifumihibi serumpr3ancaisapredictorofprimarynonresponsetoantitnfaagentsinpatientswithulcerativecolitis |